AIMS: To review the current state of research in the use of stem cells (SCs) for stress urinary incontinence (SUI) and assess the likelihood of this becoming a relevant treatment option. METHODS: The peer-reviewed literature consisting of relevant clinical and animal studies on the topic of SUI was surveyed and reviewed. RESULTS: Animal studies have demonstrated the potential utility of SCs in promoting functional recovery of the urethra after simulated childbirth injury. Research in animals suggests similar urethral recovery after injection of bone marrow derived mesenchymal SC secretions as after injection of the SCs themselves. Therefore, whether the improvements result from the injection of the SCs themselves or from their secretion of specific proteins is unclear. Early clinical trials have demonstrated the feasibility and short-term safety of injecting muscle-derived SCs into the urethra to treat SUI. CONCLUSIONS: Larger and longer-term clinical trials are needed. Nonetheless, efficacious SC-based therapy for the treatment of SUI is practical, achievable and should be available as a treatment modality in the near future.
AIMS: To review the current state of research in the use of stem cells (SCs) for stress urinary incontinence (SUI) and assess the likelihood of this becoming a relevant treatment option. METHODS: The peer-reviewed literature consisting of relevant clinical and animal studies on the topic of SUI was surveyed and reviewed. RESULTS: Animal studies have demonstrated the potential utility of SCs in promoting functional recovery of the urethra after simulated childbirth injury. Research in animals suggests similar urethral recovery after injection of bone marrow derived mesenchymal SC secretions as after injection of the SCs themselves. Therefore, whether the improvements result from the injection of the SCs themselves or from their secretion of specific proteins is unclear. Early clinical trials have demonstrated the feasibility and short-term safety of injecting muscle-derived SCs into the urethra to treat SUI. CONCLUSIONS: Larger and longer-term clinical trials are needed. Nonetheless, efficacious SC-based therapy for the treatment of SUI is practical, achievable and should be available as a treatment modality in the near future.
Authors: L K Carr; D Steele; S Steele; D Wagner; R Pruchnic; R Jankowski; J Erickson; J Huard; M B Chancellor Journal: Int Urogynecol J Pelvic Floor Dysfunct Date: 2008-06
Authors: Guiting Lin; Guifang Wang; Lia Banie; Hongxiu Ning; Alan W Shindel; Thomas M Fandel; Tom F Lue; Ching-Shwun Lin Journal: Cytotherapy Date: 2010 Impact factor: 5.414
Authors: Hannes Strasser; Rainer Marksteiner; Eva Margreiter; Germar Michael Pinggera; Michael Mitterberger; Ferdinand Frauscher; Hanno Ulmer; Martin Fussenegger; Kurt Kofler; Georg Bartsch Journal: Lancet Date: 2007-06-30 Impact factor: 79.321
Authors: Michelle Cruz; Charuspong Dissaranan; Anne Cotleur; Matthew Kiedrowski; Marc Penn; Margot Damaser Journal: Obstet Gynecol Int Date: 2011-09-21
Authors: M Vaegler; L A DaSilva; K Benz; B Amend; J Mollenhauer; W K Aicher; A Stenzl; K-D Sievert Journal: Urologe A Date: 2014-03 Impact factor: 0.639
Authors: B Amend; S Kruck; J Bedke; R Ritter; L Arenas da Silva; C Chapple; A Stenzl; K-D Sievert Journal: Urologe A Date: 2013-06 Impact factor: 0.639
Authors: Wilhelm K Aicher; Melanie L Hart; Jan Stallkamp; Mario Klünder; Michael Ederer; Oliver Sawodny; Martin Vaegler; Bastian Amend; Karl D Sievert; Arnulf Stenzl Journal: J Clin Med Date: 2014-02-24 Impact factor: 4.241